Everest Medicines (HKG:1952) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 6% in the afternoon, and the first prescription for the new nephropathy drug, Tolifukang, was launched in mainland China
Genting Xinyao B (01952) rose more than 6% in the afternoon. As of press release, it had risen 5.46% to HK$24.15, with a turnover of HK$74.9047 million.
[Broker Focus] BOC International's first purchase rating for 5 biotech companies indicates that it is firmly optimistic about the sector's potential for heavy snow
Jinwu Financial News | BOC International released an in-depth report on the biotechnology industry. In 2024, the State Council government work report first proposed speeding up the development of the innovative pharmaceutical industry, building new types of productivity such as biomantry, and encouraging entrepreneurship and equity investment. The bank believes that it will continue to introduce supporting policies in the future to promote the development momentum of pharmaceutical innovation. The bank believes that the sector has opportunities for valuation repair within 2024, mainly considering: 1) there has been a large degree of disconnection in the past year, and the bank is optimistic about the chances of Hong Kong stocks recovering compared to US stocks; 2) important overseas events such as overseas licensing/mergers and acquisitions transactions are expected to continue to be implemented in 2024.
The world's first IgA nephropathy treatment was successfully prescribed for resistance to the drug fukang, and the price per bottle was only one-tenth of the US
With the successful dispensing of Nifukang's first prescription, the cost of its treatment attracted widespread attention in the market.
Genting Xinyao (01952) announced that the world's first prescription for IgA nephropathy is resistant to the drug fukang in mainland China and opens a new era of IgA nephropathy treatment
Zhitong Finance App learned that Genting Xinyao (01952) is a biopharmaceutical company focusing on R&D, clinical development, manufacturing and commercialization of innovative drugs and vaccines. Today, it was announced that Nefucan (budesonide enteric capsules, NEFECON) has successfully implemented its first prescription in China, marking that the world's first drug for IgA nephropathy has officially benefited patients in mainland China, opening a new chapter in the treatment of the causes of IgA nephropathy in China. China is one of the countries with the highest incidence of primary glomerular diseases in the world, and as a common primary glomerular disease, IgA nephropathy accounts for about 35% to 50%. studying
Genting Xinyao Announces the World's First IgA Renal Treatment Drug Endurance in Mainland China, Launching a New Era of IgA Renal Treatment
SHANGHAI, MAY 14, 20242/BEAUTY COMMUNICATION/ -- GÜNDING XINYAO (HKEX 1952.HK), A BIOPHARMACEUTICAL COMPANY FOCUSED ON INNOVATIVE DRUG AND VACCINE R&D, CLINICAL DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION, TODAY ANNOUNCED THAT NAECHANG (PUDINE NEFECON CAPSULE) HAS SUCCESSFULLY LANDED THE FIRST PRESCRIPTION IN CHINA. Encouraging the launch of the world's first IgA kidney disease treatment drug to patients in mainland China, it opens a new chapter in the treatment of IgA kidney disease in China. China is one of the countries with the highest incidence of primary kidney disease in the world, as a common primary renal cell
Genting Xinyao (01952) announced that the Macau Drug Administration of China approved the marketing license application for a new drug using itramod (VELSIPITY) for the treatment of moderate to severe active ulcerative colitis
Genting Xinyao (01952) is a biopharmaceutical company focusing on R&D, clinical development, manufacturing and commercialization of innovative drugs and vaccines. Today, the Macau Special Administrative Region Drug Administration has officially approved the marketing license application for VELSIPITY (etrasimod) for the treatment of adult patients with moderate to severe active ulcerative colitis.
Does This Valuation Of Everest Medicines Limited (HKG:1952) Imply Investors Are Overpaying?
Key Insights The projected fair value for Everest Medicines is HK$20.13 based on 2 Stage Free Cash Flow to Equity Everest Medicines is estimated to be 22% overvalued based on current share price of
Everest Medicines' Loss Widens in 2023
Everest Medicines' (HKG:1952) net loss attributable to equity holders widened to 844.5 million yuan in the year ended Dec. 31, 2023, from a loss of 247.3 million yuan a year ago, according to a Wednes
雲頂新耀-B:2023年度報告
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 8%, and many positive results of Nifukang appeared in WCN2024
Genting Xinyao B (01952) rose more than 8%. As of press release, it had risen 8.12% to HK$23.3, with a turnover of HK$67.237 million.
[Broker Focus] Western Securities maintains Genting Xinyao (01952) holdings” rating indicates that several catalysts will soon be implemented this year
According to the Western Securities Research Report, Genting Xinyao (01952) made many advances in drug registration and commercialization in 2023. Driven by new product sales, the company's revenue increased dramatically in 2023. Eiga and Nifukang achieved sales of 99 million yuan and 21 million yuan respectively. If non-cash projects are not included, the company's gross margin exceeds 80%, and the company's innovative layout is gradually entering the harvest period.
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 6% in the intraday period and surged more than 20% this week, and the IgA nephropathy market reappeared with 10 billion acquisitions
Genting Xinyao B (01952) rose more than 6% in the intraday period, with a cumulative increase of more than 20% this week. As of press release, it rose 4.1% to HK$26.65, with a turnover of HK$87.213,400.
Cansino Biotech (06185), the leading healthcare market, surged 15.12%, and Beijing, Guangzhou, and Zhuhai issued pharmaceutical innovation support policies
Jinwu Financial News | The healthcare sector led the market. Hang Seng Healthcare Index rose 1.93%. Among the constituent stocks, Cansino Biotech (06185) rose 15.12%, Junshi Biotech (01877) rose 11.9%, Genting Xinyao (01952) rose 7.8%, Yiming Angke (01541) rose 7.79%, Pharmaceuticals (02268) rose 5.98%, and Tiger Pharmaceuticals (03347) rose 5.8%. According to the news, the Beijing Municipal Medical Security Administration issued “On “Certain Measures to Support the High-Quality Development of Innovative Pharmaceuticals by 9 Departments Including the Beijing Municipal Medical Security Administration” (202
Everest Medicines Limited (HKG:1952) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Everest Medicines Limited (HKG:1952) shareholders are probably feeling a little disappointed, since its shares fell 3.7% to HK$23.50 in the week after its latest full-year results. Revenue great
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 5% after the performance, annual revenue increased nearly 9 times, and many executives announced a voluntary ban on sales
Genting Xinyao B (01952) rose more than 5% after the results. As of press release, it had risen 5.02% to HK$23, with a turnover of HK$58,3951 million.
Genting Xinyao-B (01952) announced 2023 results and achieved revenue of 126 million yuan, an increase of 884% year-on-year
Genting Xinyao B (01952) announced its 2023 results, with revenue of RMB 126 million, an increase of 884%; R&D expenditure of approximately RMB 540 million, a decrease of 33.3% year over year; and net loss of approximately RMB 844.5 million.
EVEREST MED-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Changes in Hong Kong stocks | Genting Xinyao B (01952) is now up more than 6%. The company has appointed a chief medical officer and chief product officer, and many management have promised to voluntarily ban sales
The Zhitong Finance App learned that Genting Xinyao B (01952) is now up more than 6%. As of press release, it has risen 5.47% to HK$27, with a turnover of HK$139 million. According to the news, Genting Xinyao announced that in the important stage of implementing “independent development and successful commercialization of products based on mRNA platforms” two-wheel drive, the company appointed Ms. Zeng Qingwen as Chief Medical Officer and Mr. Liang Xu as Chief Product Officer to further strengthen the management team and enhance strategic integration between R&D, clinical development, medical affairs and marketing departments. In addition, CBC Group, the controlling shareholder of Genting Xinyao, is an executive director of the company
Press Release: Everest Medicines Strengthens Management Team With Appointments of Chief Medical Officer and Chief Product Officer
Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened its management team with the appointments of Ms. Sandra Zeng as Chief Medical Officer and Mr. Rico Liang as Chief Product Officer.
No Data